Bio Solution바이오솔루션
086820 · KOSDAQ · ₩086820 · 바이오솔루션
- Market cap
- ₩146B
- Enterprise value
- ₩154B
- P/E
- 168.6×
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- 2.1%
- Net margin
- 5.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.0% from the high
₩5,240Today: ₩5,550 – ₩5,780₩13,450
Returns
- 1W−4.6%
- 1M−11.6%
- 3M−8.9%
- 6M−50.7%
- YTD−28.6%
- 1Y−29.9%
- Volume today
- 31,912
- 0.5× the 20-day average
- Traded today
- ₩180M
- Listed shares
- 25,924,085
- EPS (12 months)
- ₩34
- Earnings yield 0.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumWeak-12.4% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Bio Solution stock overview
Bio Solution (바이오솔루션, KRX: 086820) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and manufactures cell therapy products, including autologous and allogeneic cell treatments for severe burns and cartilage defects, and is also developing NK and CAR-based anticancer cell therapies. Its shares closed at ₩5,650 on Oct 27, 2026, up 1.07% on the day, giving it a market value of ₩146B.
Key facts
- Market cap
- ₩146B
- Sector
- Biotech & Pharma
- Latest price change
- +1.07%
- As of
- Oct 27, 2026
- Main business
- The company develops and manufactures cell therapy products, including autologous and allogeneic cell treatments for severe burns and cartilage defects, and is also developing NK and CAR-based anticancer cell therapies.
Quick answers about Bio Solution
- What does Bio Solution do?
- The company develops and manufactures cell therapy products, including autologous and allogeneic cell treatments for severe burns and cartilage defects, and is also developing NK and CAR-based anticancer cell therapies. It sells human tissue models for testing (skin, cornea, oral and bronchial mucosa) with contract alternative-testing services, and supplies bio-fusion cosmetic ingredients such as plant stem cell, exosome, PDRN and collagen materials to domestic and overseas OEM and ODM customers. Its operations are based in Korea, with efforts to expand into the United States and China.
- What is the market cap of Bio Solution?
- The market capitalisation of Bio Solution was ₩146B at the close on Oct 27, 2026.
- Who are the largest shareholders of Bio Solution?
- According to the latest official filings, the largest reported holders are National Pension Service (0.15%, as of Dec 31, 2023); THE EMERGING MARKETS SMALL CAP SERIES (0.10%, as of Jul 31, 2026); Dimensional Emerging Markets Core Equity 2 ETF (0.04%, as of Jul 31, 2026).
- When is the next earnings report from Bio Solution?
- Korean companies rarely announce results dates in advance. Based on when Bio Solution filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Bio Solution?
- Yes. The National Pension Service held 0.15% of Bio Solution shares as of Dec 31, 2023.
Company profile
The company develops and manufactures cell therapy products, including autologous and allogeneic cell treatments for severe burns and cartilage defects, and is also developing NK and CAR-based anticancer cell therapies. It sells human tissue models for testing (skin, cornea, oral and bronchial mucosa) with contract alternative-testing services, and supplies bio-fusion cosmetic ingredients such as plant stem cell, exosome, PDRN and collagen materials to domestic and overseas OEM and ODM customers. Its operations are based in Korea, with efforts to expand into the United States and China.
Written by AI from the company's latest annual report.
- Korean name
- 바이오솔루션
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이정선
- Founded
- Jan 2000
- Listed
- Aug 2018
- Listed shares
- 25,924,085
- Fiscal year ends
- Month 12
- Website
- www.biosolutions.co.kr/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 23, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended: Convertible bond issue decisionAug 6, 2026
- Major management matter relevant to investorsJul 14, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Bio Solution / 바이오솔루션 / 086820 / KRX:086820
Source: KRX statistical information